Navigation Links
Amylin Pharmaceuticals to Present at the 2010 Credit Suisse Healthcare Conference
Date:11/4/2010

SAN DIEGO, Nov. 4, 2010 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Credit Suisse Healthcare Conference in Phoenix, Arizona on Thursday, November 11, 2010 at 5:30 p.m. ET / 2:30 p.m. PT. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview.

The presentation will be webcast live through the "Investors" section of Amylin's corporate website at www.amylin.com, and the recording will be made available on the website following the event. To access the live webcast, please log on to Amylin's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™
2. Amylin Pharmaceuticals to Webcast Third Quarter Results
3. Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010
4. Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development
5. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
6. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
7. Amylin Pharmaceuticals to Webcast Year-End Financial Results
8. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
9. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
10. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
11. Amylin Pharmaceuticals Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... DIEGO , Feb. 22, 2017 ... first-in-class therapies for both rare and common malignancies, ... Series B financing. The company intends to use ... cirmtuzumab and TK216, and to advance preclinical development ... Cirmtuzumab is a first-in-class anti-ROR1 monoclonal ...
(Date:2/22/2017)... 22, 2017 NetworkNewsWire Editorial Coverage: The cannabis ... in the U.S. have now legalized marijuana for medicinal or recreational ... Canada , Jamaica , ... , Uruguay and the ... cannabis in the last two years. As a result, the cannabis ...
(Date:2/22/2017)... , February 22, 2017 ... is becoming more and more prevalent today resulting ... & THC Extracts as well as other botanicals ... medicinal cannabis and marijuana therapies and their applications. ... relationships and assets designed to bring the new ...
Breaking Medicine Technology:
(Date:2/22/2017)... , ... February 22, 2017 , ... ... and 72 percent of those report that family members or friends have also ... they suffer from hearing loss wear hearing aids. One reason, suggested by 89 ...
(Date:2/22/2017)... ... February 22, 2017 , ... Social media marketing is transitioning from a ... systems. Smith & Jones’ delves into this insight and more in its latest episode ... Jones David Vener meets up with social media strategist and partner of the digital ...
(Date:2/22/2017)... Kentucky (PRWEB) , ... February 22, 2017 , ... ... Journal of Patient Safety, patient advocates stress that the patient context (age, illness ... not used as reasons to mitigate their occurrence. In addition, all ...
(Date:2/21/2017)... Australia (PRWEB) , ... February 22, 2017 , ... Author ... it is valuable for every household and family to know all about it for ... publishing world with the release of “ Detox, Digestive and Wellness Solutions ” (published ...
(Date:2/21/2017)... , ... February 21, 2017 , ... Doctors on Liens ... directed by Dr. Kendell Mendonca , to its growing network of doctors in ... including injuries stemming from car accidents such as whiplash, back pain, neck pain, hip ...
Breaking Medicine News(10 mins):